Norman Fields Gottscho Capital Management LLC Raises Position in Novo Nordisk A/S (NYSE:NVO)

Norman Fields Gottscho Capital Management LLC grew its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 45.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 63,732 shares of the company's stock after acquiring an additional 19,870 shares during the period. Novo Nordisk A/S accounts for approximately 1.8% of Norman Fields Gottscho Capital Management LLC's investment portfolio, making the stock its 15th biggest position. Norman Fields Gottscho Capital Management LLC's holdings in Novo Nordisk A/S were worth $5,482,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of NVO. Strategic Investment Solutions Inc. IL acquired a new position in Novo Nordisk A/S during the 2nd quarter valued at about $25,000. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S in the third quarter worth $28,000. Abound Wealth Management increased its holdings in shares of Novo Nordisk A/S by 257.4% in the second quarter. Abound Wealth Management now owns 218 shares of the company's stock worth $31,000 after purchasing an additional 157 shares during the period. Capital Performance Advisors LLP purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at about $42,000. Finally, Carolina Wealth Advisors LLC bought a new stake in Novo Nordisk A/S in the 3rd quarter worth approximately $48,000. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday. StockNews.com lowered Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Sunday, December 29th. BNP Paribas raised Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a research report on Monday, December 23rd. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of "Moderate Buy" and an average price target of $140.20.

Novo Nordisk A/S Trading Down 2.2 %

NYSE:NVO traded down $1.84 during trading hours on Tuesday, hitting $83.19. The company had a trading volume of 9,561,410 shares, compared to its average volume of 7,149,027. The stock has a 50-day moving average price of $102.51 and a 200 day moving average price of $120.68. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company has a market capitalization of $373.32 billion, a PE ratio of 26.92, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. Novo Nordisk A/S has a 52 week low of $81.50 and a 52 week high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.